• 1
    Flegal, K. M., Carroll, M. D., Ogden, C. K., Johnson, C. L. (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288: 17231727.
  • 2
    Korea Institute of Health and Society Affairs (1999) Korean National Health Examination Survey Ministry of Health and Welfare Seoul, Republic of Korea.
  • 3
    Pi-Sunyer, X. F. (1993) Medical hazards of obesity. Ann Intern Med 119: 655660.
  • 4
    Wellman, N. S., Friedberg, B. (2002) Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pac J Clin Nutr 11(Suppl 8): S705S709.
  • 5
    McNeely, W., Goa, K. L. (1998) Sibutramine. A review of its contribution to the management of obesity. Drugs 56: 10931124.
  • 6
    Luque, C. A., Rey, J. A. (2002) The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440: 119128.
  • 7
    Dujovne, C. A., Zavoral, J. H., Rowe, E., Mendel, C. M. (2001) Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 142: 489497.
  • 8
    Fujioka, K., Seaton, T. B., Rowe, E., et al (2000) Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2: 175187.
  • 9
    Gokcel, A., Karakose, H., Ertorer, E. M., Tanaci, N., Tutuncu, N. B., Guvener, N. (2001) Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 24: 19571960.
  • 10
    Bray, G. A., Blackburn, G. L., Ferguson, J. M., et al (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189198.
  • 11
    McMahon, F. G., Fujioka, K., Singh, B. N., et al (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160: 21852191.
  • 12
    McMahon, F. G., Weinstein, S. P., Rowe, E., Ernst, K. R., Johnson, F., Fujioka, K. (2002) Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16: 511.
  • 13
    Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., Astrup, A. (1999) The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 23: 10161024.
  • 14
    Apfelbaum, M., Vague, P., Ziegler, O., et al (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179184.
  • 15
    Expert Panel on the Identification Evaluation and Treatment of Overweight and Obesity in Adults (1998) Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158: 18551867.
  • 16
    Hazenberg, B. P. (2000) Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94: 152158.
  • 17
    Faria, A. N., Ribeiro Filho F. F., Lerario, D. D., Kohlmann, N., Ferreira, S. R., Zanella, M. T. (2002) Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol 78: 172180.
  • 18
    Zannad, F., Gille, B., Grentzinger, A., et al (2002) Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144: 508515.
  • 19
    Haddock, C. K., Poston, W. S., Dill, P. L., Foreyt, J. P., Ericsson, M. (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26: 262273.
  • 20
    O'Meara, S., Riemsma, R., Shirran, L., Mather, L., ter Riet, G. (2002) The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 6: 197.
  • 21
    Harris, R. P., Helfand, M., Woolf, S. H., et al (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20(Suppl 3): 2135.
  • 22
    Hanotin, C., Thomas, F., Jones, S. P., Leutenegger, E., Drouin, P. (1998) Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 22: 3238.
  • 23
    Seagle, H. M., Bessesen, D. H., Hill, J. O. (1998) Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 6: 115121.
  • 24
    Smith, I. G., Goulder, M. A. (2001) Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50: 505512.
  • 25
    Weintraub, M., Rubio, A., Golik, A., Byrne, L., Scheinbaum, M. L. (1991) Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 50: 330337.
  • 26
    James, W. P., Astrup, A., Finer, N., et al (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 21192125.
  • 27
    Rosenthal, R. (1979) The “file drawer problem” and tolerance for null results. Psychol Bull 86: 638641.
  • 28
    Cuellar, G. E., Ruiz, A. M., Monsalve, M. C., Berber, A. (2000) Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 8: 7182.
  • 29
    Fanghanel, G., Cortinas, L., Sanchez-Reyes, L., Berber, A. (2000) A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 24: 144150.
  • 30
    Finer, N., Bloom, S. R., Frost, G. S., Banks, L. M., Griffiths, J. (2000) Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2: 105112.
  • 31
    Wirth, A., Krause, J. (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 13311339.
  • 32
    Serrano-Rios, M., Melchionda, N., Moreno-Carretero, E. (2002) Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19: 119124.
  • 33
    Sramek, J. J., Leibowitz, M. T., Weinstein, S. P., et al (2002) Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 16: 1319.